- Report
- August 2022
- 115 Pages
Global
From €4038EUR$4,500USD£3,544GBP
- Report
- November 2023
- 135 Pages
Global
From €3589EUR$4,000USD£3,150GBP
- Report
- August 2022
- 218 Pages
Global
From €5384EUR$6,000USD£4,725GBP
€6730EUR$7,500USD£5,907GBP
- Report
- January 2024
- 250 Pages
Global
From €5707EUR$6,360USD£5,009GBP
€7134EUR$7,950USD£6,261GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2333EUR$2,600USD£2,048GBP
€2916EUR$3,250USD£2,560GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €1974EUR$2,200USD£1,733GBP
€2468EUR$2,750USD£2,166GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €1974EUR$2,200USD£1,733GBP
€2468EUR$2,750USD£2,166GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €1974EUR$2,200USD£1,733GBP
€2468EUR$2,750USD£2,166GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €1974EUR$2,200USD£1,733GBP
€2468EUR$2,750USD£2,166GBP
- Report
- August 2022
- 181 Pages
Global
From €5384EUR$6,000USD£4,725GBP
€6730EUR$7,500USD£5,907GBP
- Report
- May 2024
- 130 Pages
Global
From €4957EUR$5,524USD£4,351GBP
€5832EUR$6,499USD£5,118GBP
- Report
- May 2024
- 134 Pages
Global
From €4957EUR$5,524USD£4,351GBP
€5832EUR$6,499USD£5,118GBP
- Report
- February 2023
- 143 Pages
North America
From €3096EUR$3,450USD£2,717GBP
- Report
- January 2023
- 174 Pages
Global
From €3993EUR$4,450USD£3,505GBP
- Report
- August 2024
- 93 Pages
Global
From €3500EUR$4,178USD£3,179GBP

Treprostinil is a drug used to treat respiratory diseases such as pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It is a prostacyclin analogue, meaning it works by mimicking the effects of prostacyclin, a naturally occurring hormone in the body that helps to regulate blood pressure in the lungs. Treprostinil is administered through a variety of methods, including oral tablets, subcutaneous injections, and inhalation. It is also available in a topical form for the treatment of Raynaud's phenomenon.
Treprostinil is a relatively new drug, having been approved by the FDA in 2002. It is used to treat a variety of respiratory diseases, including PAH, CTEPH, and Raynaud's phenomenon. It is also used to treat other conditions such as sickle cell anemia and cystic fibrosis.
The treprostinil market is a growing one, with many companies offering products and services related to the drug. Some of these companies include United Therapeutics, Actelion Pharmaceuticals, GlaxoSmithKline, and Pfizer. Show Less Read more